It's worth stepping back now and then to see the shape of the work. Over the past couple of years, Rosalind has grown in a deliberate direction — toward being the place where more of your science can happen end to end, across more kinds of data, with less friction at every step. Here's the arc, and where it points next.

I've written over the past couple of years about a through-line: that rigor is the foundation, that no experiment is an island, and that our field has to move from storing data to reasoning across it. Today I want to name plainly where all of that has been heading — because I think it matters not just for Rosalind, but for the industry.

Earlier this year I argued that no experiment is an island — that the value of biological data shows up in context, not in isolation. The most common response I heard was some version of: yes, obviously, so why is it still so hard? That's exactly the right question, and I want to answer it head-on, because it points straight at the biggest shift I see coming to our field.

A single experiment is a data point. Its meaning almost always emerges in context — next to other studies, other conditions, other modalities. That's the whole premise of meta-analysis, and it's an area we've invested heavily in this release.

A few months ago I wrote about our founding bet: that rigor and provenance are the foundation everything else stands on. I want to build on that today, because a foundation is only ever worth as much as what you choose to put on top of it. And the thing I'm most convinced our field needs to put on top is context.

Discovery only matters once it's communicated. The last mile of research — turning a result into a figure a reviewer trusts and a reader understands — is where a surprising amount of a scientist's time goes, and where a surprising number of tools fall short. We've been investing in that last mile.

SimpleCell + Rosalind is Available NOW!!

In a move that will expand the boundaries of single-cell genomics, ROSALIND is excited to announce its partnership with CS Genetics, a leading innovator in genomics technology. Together, we aim to democratize access to single-cell research by combining the cutting-edge CS Genetics’ SimpleCell™ platform with ROSALIND’s powerful data analysis capabilities.

I want to start with the problem that keeps me up at night, because it's also the reason Rosalind exists. Modern biology produces an astonishing amount of data — and trusts far too little of it. That gap, between how much we generate and how much we can actually rely on, is the defining challenge of our field. It's also, I've come to believe, the biggest opportunity in it.

Earlier this month, we launched NanoString Masterclass Series, designed to enhance scientific understanding and practical skills in advanced nCounter data analysis. Dr. Ryan Friese (VP of Rosalind Customer Experience) hosts the series to share his best practices from years of working hands-on with scientists in BioPharma and Academia as a Field Application Scientist for NanoString.

Earlier this month, we launched NanoString Masterclass Series, designed to enhance scientific understanding and practical skills in advanced nCounter data analysis. Dr. Ryan Friese (VP of Rosalind Customer Experience) hosts the series to share his best practices from years of working hands-on with scientists in BioPharma and Academia as a Field Application Scientist for NanoString.